CN119015339B - Application of Elsholtzia ciliata volatile oil in the fight against coronavirus - Google Patents
Application of Elsholtzia ciliata volatile oil in the fight against coronavirusInfo
- Publication number
- CN119015339B CN119015339B CN202411166435.3A CN202411166435A CN119015339B CN 119015339 B CN119015339 B CN 119015339B CN 202411166435 A CN202411166435 A CN 202411166435A CN 119015339 B CN119015339 B CN 119015339B
- Authority
- CN
- China
- Prior art keywords
- elsholtzia
- volatile oil
- oil
- caryophyllene
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and provides an antiviral application of elsholtzia volatile oil. The elsholtzia volatile oil has the characteristics of high safety, strong drug effect, convenient administration and the like, has an inhibiting effect on both 3CLpro and PLP proteins, and can reduce acute lung injury caused by N protein. The elsholtzia volatile oil can be prepared into various application forms, is used in antiviral products, and has great market potential.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to an application of elsholtzia volatile oil in resisting coronavirus.
Background
This background information is disclosed to enhance an understanding of the general background of the invention and is not necessarily to be considered an admission or any form of suggestion that this information constitutes prior art already known to a person of ordinary skill in the art.
In recent years, respiratory tract infectious diseases seriously endanger the physical health of people, and bring about important public safety problems, in particular to novel coronaviruses in 2019. Coronaviruses (coronavirus) are a common type of RNA viruses in nature, are widely distributed and easily mutated, and have long been considered as important pathogens causing lesions of respiratory tracts and gastrointestinal tracts of mammals and birds, and have infectivity to human bodies, and can cause diseases such as cold, pneumonia and the like. Coronaviridae can be classified into the alpha, beta, gamma and delta 4 genera, 7 of which are at risk of infection to humans. The 4 types of HCoV-229E, HCoV-HKU1, HCoV-NL63 and HCoV-OC43 are widely distributed among the population, they are generally less toxic, and they are less symptomatic after infection and resemble a cold. The other 3 kinds (SARS-CoV, MERS-CoV and SARS-CoV-2) have great harm, have the characteristics of strong infectivity, high mortality, wide popularity and the like, can cause serious respiratory diseases, and can lead to lung failure and even death of patients with serious symptoms.
In the last two decades, three major coronavirus outbreaks have occurred, SARS-CoV in 2002, MERS in 2012 and SARS-CoV-2 in 2019, respectively. SARS-CoV and MERS-CoV can cause fever, dry cough, headache, dyspnea, lower respiratory tract infection, lymphopenia and diarrhea, and severe cases can even lead to death. But they are less infectious and have a shorter incubation period than SARS-CoV-2. According to world health organization statistics, by 2024, SARS-CoV-2 caused 7.7 hundred million definite cases worldwide, resulting in serious public health crisis and extensive health injury. Typical clinical symptoms are fever, dry cough, weakness, shortness of breath, severe cases can develop Acute Respiratory Distress Syndrome (ARDS), acute lung injury, septic shock, and even death.
SARS coronavirus encodes mainly two proteases, including 3C-like protease (3 CLpro) and papain-like cysteine protease (PLpro). Both play a critical role in viral replication and infection mechanisms, so inhibition of both enzymes can effectively inhibit SARS coronavirus, and is also an important target for anti-coronavirus drug discovery.
Searching for potential antiviral drugs or lead compounds with small toxic and side effects from natural plants is one of the important directions of antiviral research. Herba Moslae is dry aerial part of herba Moslae (Mosla chinensis Maxim) or Jiang Xiangru (Mosla chinensis 'Jiangxiangru') of Labiatae, and is a medicinal and edible Chinese medicine. Herba Moslae is warm in nature and pungent in flavor, has the effects of inducing sweat to relieve exterior syndrome, resolving dampness and regulating stomach, and is clinically used for treating summer-heat and damp common cold, aversion to cold and fever, headache without sweat, abdominal pain, vomiting and diarrhea and the like. CN111494456a discloses the use of water extract of herba Moslae in preparing medicine for treating coronary disease. However, herba Moslae and Jiangshi are mainly produced from Guangdong and Guangxi Provinces, fujian, hunan and Zhejiang, jiangxi and other places, and northern herba Moslae is costus root. No research report on resisting coronavirus aiming at the elsholtzia volatile oil is available.
Disclosure of Invention
The invention provides an application of elsholtzia volatile oil in resisting coronavirus.
In order to achieve the above purpose, the present invention adopts the following technical scheme.
An application of herba Moslae volatile oil in preparing anti-coronavirus medicine is provided.
The coronavirus is a human coronavirus (HCoV).
The application is as 3CL and PLP protein inhibitor or for alleviating acute lung injury.
The herba Moslae volatile oil is obtained by extracting dry aerial part of herba Moslae (Elsholtzia stauntoni Benth) with steam distillation method.
The main components of the elsholtzia volatile oil comprise trans-caryophyllene, alpha-caryophyllene, palmitoleic acid, caryophyllene oxide, alpha-pinene, delta-juniper, and iso-orange epoxide, wherein the content of the main components is more than 90wt%, the content of the trans-caryophyllene is 65-70 wt%, and the content of the alpha-caryophyllene is 8-12 wt%.
The invention has the following advantages:
The invention provides an application of elsholtzia volatile oil in resisting coronavirus. The elsholtzia volatile oil has the characteristics of high safety, strong drug effect, convenient administration and the like, has an inhibiting effect on both 3CLpro and PLP proteins, and can reduce acute lung injury caused by N protein. The elsholtzia volatile oil can be prepared into various application forms, is used in antiviral products, and has great market potential.
Drawings
FIG. 1 is a total ion flow diagram of herba Moslae oil;
FIG. 2 is a graph showing the inhibition ratio of PLP (A) and 3CLpro (B) by elsholtzia oil at different concentrations;
FIG. 3 is a graph showing the fit of the inhibition ratios of different concentrations of elsholtzia oil to HCoV-229E;
FIG. 4 shows the expression levels of cellular inflammatory factor mRNA in various treatments;
FIG. 5 shows lung function in different treated mice;
FIG. 6 shows the expression levels of inflammatory factor mRNA in lung tissue of mice treated differently.
Detailed Description
The present invention will be further described with reference to examples and drawings, but the present invention is not limited to the examples.
Example 1 inhibition of 3C-like protease (3 CL) and papain-like protease (PLP) by Elsholtzia ciliata oil
1.3 Preparation of CLpro and PLP proteins
According to the description in the description of inhibition of SARS-CoV-23CLpro and PLP activity by 6 Chinese patent drugs (2023), recombinant plasmids pGEX-6P-1-SARS-CoV-2-3CL and pET-32a (+) -SARS-CoV-2-PLP are obtained, and after transformation of the recombinant plasmids into BL21 competence, recombinant E.coli is obtained for expressing two proteins, the recombinant bacteria are cultured and the cell lysate is purified by HISTRAP HP affinity chromatography column after induction by IPTG, thus obtaining 3CL and PLP proteins of SARS-CoV-2.
2. Medicine and component analysis
Elsholtzia oil (purity: 98%, chinese pharmacopoeia 2020 edition 2204 volatile oil assay A method) is purchased from Jiangxi Hengcheng natural perfume oil Limited company (batch number: 20220620) and extracted by using a water vapor distillation method of Elsholtzia.
(1) Sample processing
10 Mu L of elsholtzia oil is placed in an EP tube of 2 mL, 990 mu L of ethyl acetate is added, and the mixture is uniformly mixed by ultrasonic waves. Sucking with a disposable syringe of 1 mL, and introducing into a sample bottle through a microporous organic filter membrane of 0.45 μm to obtain the sample solution to be detected.
(2) Analysis conditions
The chromatographic column is an HP-5MS column (30 m multiplied by 0.25 multiplied by mm multiplied by 0.25 mu m), the carrier gas is high-purity helium gas, the flow rate is 1mL/min, the split feeding is 50:1, the feeding amount is 1.0 mu L, the temperature programming is carried out (initial 70 ℃ C., the speed is 10 ℃ C./min and is 100 ℃ C., the speed is 3 ℃ C./min and is 160 ℃ C., the speed is 5 ℃ C./min and is 190 ℃ C., and the retention is 1 min).
The mass spectrum condition is EI ion source, ion source temperature is 230 ℃, ionization energy is 70 eV, and mass scanning range is m/z 12-550.
(3) Results
The total ion flow diagram is shown in fig. 1. And calculating the percentage of each integral chromatographic peak to the total peak area by adopting an area normalization method, and analyzing mass spectrum data of the elsholtzia oil component obtained by GC-MS, wherein all the data are analyzed by adopting NIST 2.3 map library retrieval and automatic deconvolution technology.
TABLE 1 identification of essential chemical Components of Elsholtzia oil
51 Components were separated from elsholtzia oil, 26 of which were identified as 98% of the total peak area, see table 1. Wherein the trans-caryophyllene, alpha-caryophyllene, palmitoleic acid, caryophyllene oxide, alpha-pinene, delta-juniper and isobergamotene epoxide content are all more than 1%, and the trans-caryophyllene, alpha-caryophyllene, palmitoleic acid, caryophyllene oxide, alpha-pinene, delta-juniper and isobergamotene epoxide content are main components accounting for 92.24% of the total peak area.
2. IC of elsholtzia oil to 3CLpro and PLP 50
Elsholtzia oil was diluted with DMSO to a series of concentration solutions starting from 100 μg/mL, ebselen or GRL0617 was diluted with DMSO to a series of concentration solutions starting from 1.000 μmol/L and 50.000 μmol/L, respectively, and its inhibition rates for 3CLpro, PLP and IC 50 were determined as follows:
In a 96-well plate with a transparent bottom, 3CLpro or PLP (40. Mu.L/well, final concentration 100 nmol/L) was mixed with elsholtzia oil (10. Mu.L/well), elvan selenium (10. Mu.L/well) or GRL0617 (10. Mu.L/well), after incubation at room temperature 30 min, 3CLpro or PLP fluorogenic substrate (50. Mu.L/well, final concentration 25 nmol/L or 30 nmol/L) was added, and fluorescence intensity was immediately detected with a multifunctional enzyme-labeled instrument under conditions of gain value 100, temperature room temperature, excitation light 336 nm (3 CLpro), 360 nm (PLP), emission light 490 nm, detection interval 30 s, total detection time 60 min. The drug inhibition rate is calculated according to the increase value of the fluorescence intensity of different drugs in the reaction 1 h, and the formula is
Inhibition ratio =×100%;
IC 50 for 3CLpro, PLP was fitted according to the inhibition ratios at the different concentrations.
The fitting curve is shown in FIG. 2, wherein IC 50 of elsholtzia oil to 3CLpro is (45.05+ -3.78) μg/mL, IC 50 of ebselen to 3CLpro is (29.34+ -1.65) μg/L, IC 50 of elsholtzia oil to PLP is (8.002 + -1.395) μg/mL, and IC 50 of GRL0617 to PLP is (1.26+ -0.0402) mg/L. The above results show that elsholtzia oil has an inhibitory effect on both 3CLpro and PLP, and has a stronger inhibitory effect on PLP.
Example 2 in vitro anti-HCoV-229E effect of Elsholtzia oil
The experiments were performed commercially by purchasing HCoV-229E and dissolving it in DMSO to a maximum solubility concentration, and twice diluting the cell-maintaining solution to obtain 6 test solutions of the volatile components of the traditional Chinese medicine including the maximum solubility. Huh-7 cells (1.5X10 5/well) were seeded in 24-well plates, incubated in 37℃5% CO 2 cell incubator for 24h, and the culture was discarded. 500. Mu.L of the test solution was added to each well, the culture solution was discarded after 4h actions, 500. Mu.L of HCoV-229E virus dilution (MOI=0.1 to dilute the virus with the test solution) was added to each well, the culture solution was discarded after continuing 1 action h actions, and 500. Mu.L of the test solution was added to each well. At the same time, virus control wells without drug effect were established. After 48: 48 h culture in a 34 ℃ and 5% CO 2 cell incubator, repeated freeze thawing is carried out for 3 times, the virus supernatant is centrifuged in a low-temperature high-speed centrifuge and stored in an ultralow-temperature refrigerator at-80 ℃.
TCID 50 of the collected supernatant was determined using CCK8 method and Reed-Muench method. The drug effect, namely the inhibition rate of the elsholtzia oil to HCoV-229E, is calculated according to the TCID 50 result, and the formula is as follows:
Inhibition ratio = ×100%;
6 Gradients were 2-fold diluted from the highest final concentration of 50 μg/mL, each concentration of drug was tested as described above, and the results were fitted to give IC 50.
A graph of the fit of elsholtzia oil to HCoV-229E is shown in FIG. 3, wherein IC 50 is 1.602+ -0.597 μg/mL.
Example 3 in vitro anti-N protein lesions and inflammation effects of Elsholtzia oil
1. N protein acquisition
The SARS-CoV-2N protein recombinant plasmid pET28A-SARS-CoV-2-N plasmid is designed according to the plasmid pET-32a (+) -N-protein taught by Shanghai university Tao Shengce, and after transformation into BL21 competence, endotoxin is removed after induction purification, split charging and preservation are carried out, polymyxin B (250 mug/mL) is added before the experiment, 1h is incubated in a 37 ℃ biochemical incubator, and the condition that no endotoxin interferes with the experiment is ensured.
2. Protection effect of elsholtzia oil on cytopathy caused by N protein
Human lung epithelial cell line BEAS-2B (B2B) was cultured according to the standard procedure of the specification and used for the experiment:
B2B cells were plated into 96-well plates at a concentration of 1.6X10 5/mL and returned to 37℃and cultured in a 5% CO 2 cell incubator, after plating 6 h, the stock solution was discarded, PBS was washed down, serum-free DMEM was added for starvation culture overnight, and Elsholtzia grass oil groups (cell-grade DMSO was dissolved at a final concentration of 0.1. Mu.g/mL), blank control groups, model groups (N protein+0.1% DMSO) were set, OD 450 was detected and the protection rate was calculated according to the following formula:
Protection ratio = ×100%。
The protection rate of the elsholtzia oil on cytopathy caused by N protein is 31.61 +/-3.347.
3. Effects of Elsholtzia oil on cell inflammation caused by N protein
B2B cells were plated in 96-well plates at a concentration of 1.6X10 5/mL and returned to 37℃and 5% CO 2 cell incubator for continuous culture, after 6-h plates were plated, the stock culture was discarded, PBS was washed down, serum-free DMEM was added for starvation culture overnight, and the mRNA expression of inflammatory factors IL-6, IL-8, IL-18, IL-1β and TNF- α were detected by setting an elsholtzia oil group (final concentration of 0.1. Mu.g/mL), a blank control group and a model group.
The results are shown in FIG. 4, which shows that elsholtzia oil has a down-regulation trend on the secretion of cell inflammatory factors caused by N protein.
EXAMPLE 4 Elsholtzia oil against N protein induced acute lung injury in mice
SPF grade C57BL/6JNifdc Male mice, four weeks old, body weight 17-19 g, lot number 110011231110791025, purchased from Beijing Vitolith laboratory animal technologies Co., ltd. [ SCXK (Beijing) 2022-0006]. The mice eat and drink water freely during the feeding period, the lamplight is circulated by 12h, the room temperature is maintained at 22-25 ℃, and the humidity is 40-60%. Randomly dividing into 3 groups of 3, normal group, herba Moslae oil group, and model group.
After anesthesia of 150 mu L of 1% pentobarbital sodium, 25 mu L of 1% elsholtzia oil is atomized every day by the administration group, 25 mu L of physiological saline is atomized by the normal group of the model group, and the administration is performed for 3 days. The 3 rd weather tube instils 50 μl (60 μg) of N protein stimulated dosing and model group. Immediately after 24 h of N protein stimulation, lung function is detected, sacrificed, lung, spleen and thymus are weighed, organ indexes are calculated, and relative expression of mRNA of inflammatory factors IL-6, IL-1 beta, IFN-gamma and TNF-alpha is detected by the reserved lung tissue.
The lung function of the mice is shown in fig. 5, after N protein stimulation, the respiratory frequency, the tidal volume, the minute ventilation volume, the cumulative volume, the maximum expiratory flow, the maximum inspiratory flow, the relative time and the Penh are obviously up-regulated, the inspiratory time and the expiratory time are obviously down-regulated, and the respiratory function state of the mice can be obviously regulated after the elsholtzia oil treatment, so that the mice can be recovered to the degree which is not different from the normal group.
After dissecting the mice, there was no obvious difference in the indices of the individual organs.
The expression of lung tissue inflammatory factor mRNA is shown in figure 6. Elsholtzia herb oil can down regulate the relative expression of four inflammatory factors, IL-6, IL-1 beta, IFN-gamma and TNF-alpha.
The above results show that elsholtzia oil can resist acute lung injury of mice caused by N protein.
Claims (2)
1. The application of the elsholtzia volatile oil in preparing the anti-coronavirus medicament is characterized in that the elsholtzia volatile oil is obtained by extracting dry aerial parts of the costustoot (Elsholtzia stauntoni Benth) by a steam distillation method;
The main components of the elsholtzia volatile oil comprise trans-caryophyllene, alpha-caryophyllene, palmitoleic acid, caryophyllene oxide, alpha-pinene, delta-juniper, and isobergamotene epoxide, wherein the content of the main components is more than 90wt%, the content of the trans-caryophyllene is 65-70 wt%, and the content of the alpha-caryophyllene is 8-12 wt%;
The coronavirus is HCoV.
2. The use of elsholtzia volatile oil according to claim 1 in the manufacture of a medicament for the prevention and treatment of acute lung injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411166435.3A CN119015339B (en) | 2024-08-23 | 2024-08-23 | Application of Elsholtzia ciliata volatile oil in the fight against coronavirus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411166435.3A CN119015339B (en) | 2024-08-23 | 2024-08-23 | Application of Elsholtzia ciliata volatile oil in the fight against coronavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN119015339A CN119015339A (en) | 2024-11-26 |
| CN119015339B true CN119015339B (en) | 2026-04-17 |
Family
ID=93528370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411166435.3A Active CN119015339B (en) | 2024-08-23 | 2024-08-23 | Application of Elsholtzia ciliata volatile oil in the fight against coronavirus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119015339B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494456A (en) * | 2020-04-08 | 2020-08-07 | 浙江省疾病预防控制中心 | Application of water extracts of Rhizoma Radix in the preparation of anti-new coronavirus drugs |
| CN113855654A (en) * | 2020-07-28 | 2021-12-31 | 苏州佰然基因科技有限公司 | A composition for preventing and treating coronavirus infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1267110C (en) * | 2002-12-09 | 2006-08-02 | 张瑞祥 | Medicinal use of fenugreek and the volatile oil of fenugreek |
| KR102383026B1 (en) * | 2019-07-30 | 2022-04-05 | 한국 한의학 연구원 | Composition comprising compound from extract of Dryopteris crassirhizoma for preventing or treating coronavirus infection |
| CN111150755B (en) * | 2020-02-28 | 2022-04-12 | 雷允上药业集团有限公司 | Traditional Chinese medicine composition for preventing and treating viral diseases and application thereof |
| CN112516276A (en) * | 2020-10-15 | 2021-03-19 | 湖北思达康中药科技有限公司 | Traditional Chinese medicine for preventing novel coronavirus pneumonia, preparation process thereof and traditional Chinese medicine beverage |
| CN113773907A (en) * | 2021-07-27 | 2021-12-10 | 吉林化工学院 | Preparation and detection of chemical constituents of a kind of volatile oil from different parts of A. |
-
2024
- 2024-08-23 CN CN202411166435.3A patent/CN119015339B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494456A (en) * | 2020-04-08 | 2020-08-07 | 浙江省疾病预防控制中心 | Application of water extracts of Rhizoma Radix in the preparation of anti-new coronavirus drugs |
| CN113855654A (en) * | 2020-07-28 | 2021-12-31 | 苏州佰然基因科技有限公司 | A composition for preventing and treating coronavirus infection |
Non-Patent Citations (1)
| Title |
|---|
| 超临界流体CO2萃取法研究木香薷精油化学成分;郑尚珍等;《西北师范大学学报（自然科学版）》;20011231;第37卷(第3期);第37-40页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119015339A (en) | 2024-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niraj et al. | A review on scope of immuno-modulatory drugs in Ayurveda for prevention and treatment of Covid-19 | |
| CN113332363B (en) | Application of tea extract and its composition in anti-coronavirus | |
| CN113244211A (en) | Application of baicalein and baicalin as main components of radix Scutellariae and their composition in resisting coronavirus | |
| CN115770236B (en) | Application of turmeric in preparation of anti-respiratory virus medicine | |
| CN103028001A (en) | Traditional Chinese medicine prescription for relieving asthma, relieving cough and resisting inflammatory, preparation method and application thereof | |
| CN113181229B (en) | Application of cabbage type rape-isatis tinctoria G monomer addition system in inhibiting novel coronavirus SARS-CoV-2 | |
| CN119015339B (en) | Application of Elsholtzia ciliata volatile oil in the fight against coronavirus | |
| CN102988469A (en) | Traditional Chinese medicine composition for preventing and treating influenza virus infection as well as preparation method and application thereof | |
| CN113101310B (en) | Medicine for preventing and/or treating coronavirus infection and preparation method thereof | |
| CN106038695B (en) | Use of avocado extract, avocadol B and (2R,4R) -1,2, 4-trihydroxyheptadeca-16-alkyne, and health food containing avocado extract | |
| Pang et al. | Antiviral effects of aqueous extract from Spatholobus suberectus Dunn. against coxsackievirus B3 in mice | |
| CN118477064A (en) | Application of baicalin in the fight against largemouth bass rhabdovirus | |
| ES2400495T3 (en) | Activity against dengue extracts of Cissampelos pareira | |
| CN107468682A (en) | Application of the mangiferin in antiviral drugs is prepared | |
| US20220175868A1 (en) | INHIBITION OF SARS-CoV-2 VIRUS BY ARUM PALAESTINUM | |
| CN101843612B (en) | Application of isoorientin in preparation of medicament for resisting respiratory syncytial virus | |
| CN113082080B (en) | Application of illicium plants or extracts thereof in preparation of anti-animal virus drugs | |
| CN119700764B (en) | Application of enpipivermectin in the preparation of drugs against Chikungunya virus infection | |
| CN119661514B (en) | Herba corydalis Bungeanae total alkaloid extract for preventing and treating hyperuricemia, and preparation method and application thereof | |
| TWI895230B (en) | Use of ovatodiolide in the manufacture of medical composition for improving blood oxygen saturation in a subject | |
| CN110251538A (en) | Application of Yaoyao rapeseed extract in preparation of medicine for treating pneumonia caused by Klebsiella infection | |
| CN118490769A (en) | Combined type blackberry lily antiviral oral medicine | |
| CN112386641B (en) | Traditional Chinese medicine composition for treating pulmonary tuberculosis and preparation method and traditional Chinese medicine preparation thereof | |
| CN112957388B (en) | Application of brassica napus-isatis tinctoria E monomer addition system in inhibiting influenza virus | |
| Liu et al. | Paeoniae Radix Rubra extract inhibits largemouth bass ranavirus (LMBV) replication by suppressing inflammatory response and oxidative stress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |